JP2021050226A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021050226A5 JP2021050226A5 JP2020204298A JP2020204298A JP2021050226A5 JP 2021050226 A5 JP2021050226 A5 JP 2021050226A5 JP 2020204298 A JP2020204298 A JP 2020204298A JP 2020204298 A JP2020204298 A JP 2020204298A JP 2021050226 A5 JP2021050226 A5 JP 2021050226A5
- Authority
- JP
- Japan
- Prior art keywords
- fgf23 antibody
- seq
- fgf23
- antibody according
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 201000010103 fibrous dysplasia Diseases 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 230000003553 hypophosphatemic effect Effects 0.000 claims 3
- 208000010061 Autosomal Dominant Polycystic Kidney Diseases 0.000 claims 2
- 201000003674 autosomal dominant hypophosphatemic rickets Diseases 0.000 claims 2
- 201000003672 autosomal recessive hypophosphatemic rickets Diseases 0.000 claims 2
- 208000011580 syndromic disease Diseases 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 208000010444 Acidosis Diseases 0.000 claims 1
- 102100024802 Fibroblast growth factor 23 Human genes 0.000 claims 1
- 101001051973 Homo sapiens Fibroblast growth factor 23 Proteins 0.000 claims 1
- 208000029663 Hypophosphatemia Diseases 0.000 claims 1
- 206010027417 Metabolic acidosis Diseases 0.000 claims 1
- 230000001594 aberrant effect Effects 0.000 claims 1
- 208000022185 autosomal dominant polycystic kidney disease Diseases 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 208000007442 rickets Diseases 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462009474P | 2014-06-09 | 2014-06-09 | |
| US62/009,474 | 2014-06-09 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016569651A Division JP6808493B2 (ja) | 2014-06-09 | 2015-05-29 | 最適な骨形成のための血清リンの効果的かつ効率的な制御 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021050226A JP2021050226A (ja) | 2021-04-01 |
| JP2021050226A5 true JP2021050226A5 (https=) | 2021-05-13 |
| JP6993490B2 JP6993490B2 (ja) | 2022-02-03 |
Family
ID=54769049
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016569651A Active JP6808493B2 (ja) | 2014-06-09 | 2015-05-29 | 最適な骨形成のための血清リンの効果的かつ効率的な制御 |
| JP2020204298A Active JP6993490B2 (ja) | 2014-06-09 | 2020-12-09 | 最適な骨形成のための血清リンの効果的かつ効率的な制御 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016569651A Active JP6808493B2 (ja) | 2014-06-09 | 2015-05-29 | 最適な骨形成のための血清リンの効果的かつ効率的な制御 |
Country Status (25)
| Country | Link |
|---|---|
| US (5) | US10639360B2 (https=) |
| EP (3) | EP3845245B1 (https=) |
| JP (2) | JP6808493B2 (https=) |
| KR (4) | KR102947335B1 (https=) |
| CN (1) | CN106604743A (https=) |
| AR (2) | AR100689A1 (https=) |
| AU (1) | AU2015275128C1 (https=) |
| BR (2) | BR112016028567A2 (https=) |
| CA (1) | CA2949234C (https=) |
| CL (1) | CL2016003179A1 (https=) |
| CY (1) | CY1124328T1 (https=) |
| DK (2) | DK3151859T3 (https=) |
| ES (2) | ES3040805T3 (https=) |
| FI (1) | FI3845245T3 (https=) |
| HR (2) | HRP20210250T1 (https=) |
| HU (2) | HUE053271T2 (https=) |
| LT (2) | LT3845245T (https=) |
| MX (2) | MX381052B (https=) |
| PE (1) | PE20170248A1 (https=) |
| PL (2) | PL3845245T3 (https=) |
| PT (2) | PT3845245T (https=) |
| RS (2) | RS61443B1 (https=) |
| SI (2) | SI3151859T1 (https=) |
| SM (2) | SMT202500342T1 (https=) |
| WO (1) | WO2015191312A1 (https=) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2559228C (en) | 2004-04-21 | 2016-06-21 | Enobia Pharma Inc. | Bone delivery conjugates and method of using same to target proteins to bone |
| MX381052B (es) | 2014-06-09 | 2025-03-12 | Ultragenyx Pharmaceutical Inc | El control efectivo y eficaz del fosfato serico para una osificacion optima. |
| WO2016007873A1 (en) | 2014-07-11 | 2016-01-14 | The Regents Of The University Of Michigan | Compositions and methods for treating craniosynostosis |
| MX389350B (es) | 2014-12-05 | 2025-03-19 | Alexion Pharma Inc | Fosfatasas alcalinas recombinantes y usos de las mismas para el tratamiento de convulsiones. |
| JP6868561B2 (ja) | 2015-01-28 | 2021-05-12 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | アルカリホスファターゼ欠損を有する被験者を治療する方法 |
| CN108350440A (zh) | 2015-08-17 | 2018-07-31 | 阿雷克森制药公司 | 碱性磷酸酯的制造 |
| JP6868617B2 (ja) | 2015-09-28 | 2021-05-12 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | 低ホスファターゼ血症の組織非特異的アルカリホスファターゼ（ｔｎｓａｌｐ）酵素補充療法に有効な投薬計画の特定 |
| JP2018533571A (ja) | 2015-10-30 | 2018-11-15 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | 患者の頭蓋縫合早期癒合症を治療するための方法 |
| WO2017155569A1 (en) | 2016-03-08 | 2017-09-14 | Alexion Pharmaceuticals, Inc. | Methods for treating hypophosphatasia in children |
| US10898549B2 (en) | 2016-04-01 | 2021-01-26 | Alexion Pharmaceuticals, Inc. | Methods for treating hypophosphatasia in adolescents and adults |
| JP7613826B2 (ja) | 2016-04-01 | 2025-01-15 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | アルカリホスファターゼによって筋力低下を治療すること |
| US10988744B2 (en) | 2016-06-06 | 2021-04-27 | Alexion Pharmaceuticals, Inc. | Method of producing alkaline phosphatase |
| EP3500289B1 (en) | 2016-08-18 | 2024-10-09 | Alexion Pharmaceuticals, Inc. | Asfotase alfa for use in treating tracheobronchomalacia |
| CN106709662B (zh) * | 2016-12-30 | 2021-07-02 | 山东鲁能软件技术有限公司 | 一种电力设备运行工况划分方法 |
| EP3600383A4 (en) | 2017-03-31 | 2020-10-28 | Alexion Pharmaceuticals, Inc. | METHODS OF TREATMENT OF HYPOPHOSPHATASIA (HPP) IN ADULTS AND ADOLESCENTS |
| US11913039B2 (en) | 2018-03-30 | 2024-02-27 | Alexion Pharmaceuticals, Inc. | Method for producing recombinant alkaline phosphatase |
| US12268733B2 (en) | 2018-08-10 | 2025-04-08 | Alexion Pharmaceuticals, Inc. | Methods of treating neurofibromatosis type 1 and related conditions with alkaline phosphatase |
| BR112021019337A2 (pt) * | 2019-03-29 | 2021-12-07 | Atarga Llc | Anticorpo anti-fgf23 |
| CA3161266A1 (en) | 2019-12-09 | 2021-06-17 | Alexion Pharmaceuticals, Inc. | Alkaline phosphatase polypeptides and methods of use thereof |
| AU2021337652B2 (en) | 2020-09-04 | 2025-01-30 | Alexion Pharmaceuticals, Inc. | Methods for treating bone mineralization disorders |
| BR112023016048A2 (pt) | 2021-02-12 | 2023-11-14 | Alexion Pharma Inc | Polipeptídeos de fosfatase alcalina e métodos de uso dos mesmos |
| EP4676955A2 (en) * | 2023-03-10 | 2026-01-14 | Ultragenyx Pharmaceutical Inc. | Human fgf23-binding antibodies with improved affinity and efficacy |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| HUT35524A (en) | 1983-08-02 | 1985-07-29 | Hoechst Ag | Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US5091513A (en) | 1987-05-21 | 1992-02-25 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| US5096815A (en) | 1989-01-06 | 1992-03-17 | Protein Engineering Corporation | Generation and selection of novel dna-binding proteins and polypeptides |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| ATE207080T1 (de) | 1991-11-25 | 2001-11-15 | Enzon Inc | Multivalente antigen-bindende proteine |
| AU2005202100A1 (en) | 1999-05-11 | 2005-06-09 | Ortho-Mcneil Pharmaceutical, Inc. | Pharmacokinetic and pharmacodynamic modeling of erythropoietin administration |
| ES2336887T5 (es) | 2000-03-30 | 2019-03-06 | Whitehead Inst Biomedical Res | Mediadores de interferencia por ARN específicos de secuencias de ARN |
| ATE461213T1 (de) | 2000-07-19 | 2010-04-15 | Advanced Res & Tech Inst | Neuer fibroblastwachstumsfaktor (fgf23) und methoden zur verwendung |
| EP2233571B1 (en) | 2000-08-11 | 2012-11-07 | Kyowa Hakko Kirin Co., Ltd. | Polypeptide regulating phosphate metabolism, calcium metabolism, calcification and vitamin D metabolism and DNAS encoding the same |
| CA2430013C (en) | 2000-11-30 | 2011-11-22 | Medarex, Inc. | Transgenic transchromosomal rodents for making human antibodies |
| JP4527982B2 (ja) * | 2001-12-28 | 2010-08-18 | 協和発酵キリン株式会社 | 線維芽細胞増殖因子−２３に対する抗体 |
| EP1833848A2 (en) * | 2004-12-09 | 2007-09-19 | Lajolla Institute for Allergy and Immunology | Novel tnf receptor regulatory domain |
| US8158725B2 (en) | 2005-08-22 | 2012-04-17 | Bridgestone Corporation | Functionalized polymers and tires therefrom |
| US7883705B2 (en) | 2007-02-14 | 2011-02-08 | Kyowa Hakko Kirin Co., Ltd. | Anti FGF23 antibody and a pharmaceutical composition comprising the same |
| US8889621B2 (en) | 2009-10-30 | 2014-11-18 | New York University | Inhibiting binding of FGF23 to the binary FGFR-Klotho complex for the treatment of hypophosphatemia |
| WO2012050673A1 (en) | 2010-10-14 | 2012-04-19 | Wisconsin Alumni Research Foundation | Methods for the treatment of x-linked hypophosphatemia and related disorders |
| US9982023B2 (en) * | 2011-11-15 | 2018-05-29 | Sanford-Burnham Medical Research Institute | Compositions and methods for treating autoimmune and inflammatory disorders |
| MX381052B (es) | 2014-06-09 | 2025-03-12 | Ultragenyx Pharmaceutical Inc | El control efectivo y eficaz del fosfato serico para una osificacion optima. |
-
2015
- 2015-05-29 MX MX2016016296A patent/MX381052B/es unknown
- 2015-05-29 CA CA2949234A patent/CA2949234C/en active Active
- 2015-05-29 SI SI201531522T patent/SI3151859T1/sl unknown
- 2015-05-29 BR BR112016028567A patent/BR112016028567A2/pt not_active Application Discontinuation
- 2015-05-29 KR KR1020247017683A patent/KR102947335B1/ko active Active
- 2015-05-29 WO PCT/US2015/033226 patent/WO2015191312A1/en not_active Ceased
- 2015-05-29 LT LTEP20208220.2T patent/LT3845245T/lt unknown
- 2015-05-29 ES ES20208220T patent/ES3040805T3/es active Active
- 2015-05-29 DK DK15806501.1T patent/DK3151859T3/da active
- 2015-05-29 PT PT202082202T patent/PT3845245T/pt unknown
- 2015-05-29 KR KR1020177000293A patent/KR20170013993A/ko not_active Ceased
- 2015-05-29 US US14/725,320 patent/US10639360B2/en active Active
- 2015-05-29 RS RS20210173A patent/RS61443B1/sr unknown
- 2015-05-29 LT LTEP15806501.1T patent/LT3151859T/lt unknown
- 2015-05-29 HR HRP20210250TT patent/HRP20210250T1/hr unknown
- 2015-05-29 KR KR1020217024284A patent/KR20210099180A/ko not_active Ceased
- 2015-05-29 HR HRP20251099TT patent/HRP20251099T1/hr unknown
- 2015-05-29 PE PE2016002698A patent/PE20170248A1/es unknown
- 2015-05-29 SM SM20250342T patent/SMT202500342T1/it unknown
- 2015-05-29 EP EP20208220.2A patent/EP3845245B1/en active Active
- 2015-05-29 EP EP25184948.5A patent/EP4647444A3/en active Pending
- 2015-05-29 FI FIEP20208220.2T patent/FI3845245T3/fi active
- 2015-05-29 ES ES15806501T patent/ES2851674T3/es active Active
- 2015-05-29 AR ARP150101715A patent/AR100689A1/es unknown
- 2015-05-29 BR BR122023023102-3A patent/BR122023023102A2/pt not_active Application Discontinuation
- 2015-05-29 PT PT158065011T patent/PT3151859T/pt unknown
- 2015-05-29 KR KR1020267009825A patent/KR20260051107A/ko active Pending
- 2015-05-29 AU AU2015275128A patent/AU2015275128C1/en active Active
- 2015-05-29 PL PL20208220.2T patent/PL3845245T3/pl unknown
- 2015-05-29 SM SM20210096T patent/SMT202100096T1/it unknown
- 2015-05-29 HU HUE15806501A patent/HUE053271T2/hu unknown
- 2015-05-29 JP JP2016569651A patent/JP6808493B2/ja active Active
- 2015-05-29 CN CN201580039280.XA patent/CN106604743A/zh active Pending
- 2015-05-29 SI SI201532076T patent/SI3845245T1/sl unknown
- 2015-05-29 HU HUE20208220A patent/HUE073105T2/hu unknown
- 2015-05-29 PL PL15806501T patent/PL3151859T3/pl unknown
- 2015-05-29 DK DK20208220.2T patent/DK3845245T3/da active
- 2015-05-29 RS RS20250889A patent/RS67294B1/sr unknown
- 2015-05-29 EP EP15806501.1A patent/EP3151859B1/en active Active
-
2016
- 2016-12-08 MX MX2021003740A patent/MX2021003740A/es unknown
- 2016-12-09 CL CL2016003179A patent/CL2016003179A1/es unknown
-
2020
- 2020-03-26 US US16/831,179 patent/US11202822B2/en active Active
- 2020-12-09 JP JP2020204298A patent/JP6993490B2/ja active Active
-
2021
- 2021-02-23 CY CY20211100154T patent/CY1124328T1/el unknown
- 2021-11-12 US US17/525,738 patent/US11771748B2/en active Active
-
2023
- 2023-08-07 US US18/366,447 patent/US12358976B2/en active Active
- 2023-11-14 AR ARP230103059A patent/AR131056A2/es unknown
-
2025
- 2025-06-11 US US19/235,347 patent/US20260035449A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021050226A5 (https=) | ||
| JP2017524656A5 (https=) | ||
| Presant et al. | Liposomal daunorubicin treatment of HIV-associated Kaposi's sarcoma | |
| RU2011134499A (ru) | Композиция 4-амино-2-(2,6-диоксопиперидин-3-ил)изоиндолин-1,3-диона | |
| JP2021530541A5 (https=) | ||
| JP2020521797A5 (https=) | ||
| JP2005508338A5 (https=) | ||
| CN115605194A (zh) | 过度炎症综合征的治疗 | |
| JP2001513110A (ja) | 腫瘍治療方法 | |
| Brogden et al. | Timolol: a preliminary report of its pharmacological properties and therapeutic efficacy in angina and hypertension | |
| Cheng et al. | A randomized prospective comparison of oral levofloxacin plus intraperitoneal (IP) vancomycin and IP netromycin plus IP vancomycin as primary treatment of peritonitis complicating CAPD | |
| James et al. | Paroxysmal ventricular arrhythmias and familial sudden death associated with neural lesions in the heart | |
| Jefferson | Lyell's toxic epidermal necrolysis: a staphylococcal aetiology? | |
| HUP0401633A2 (hu) | Irbesartan alkalmazása pulmonális magas vérnyomás megelőzésére vagy kezelésére alkalmas gyógyszerkészítmény előállítására | |
| TW202237103A (zh) | 用於治療抑鬱症的ｎｒ２ｂ－ｎｍｄａ受體ｎａｍ之劑量方案 | |
| PT891186E (pt) | Administração nasal de agentes para o tratamento de emese tardia | |
| JP2022526643A5 (https=) | ||
| Wolfson et al. | Conversion of atrial fibrillation and flutter by propranolol | |
| Channer | The drug treatment of atrial fibrillation. | |
| JP5663498B2 (ja) | 網膜色素変性症を処置するためのペプチド模倣環状化合物 | |
| JPH0219093B2 (https=) | ||
| IL320111A (en) | Cnp compounds | |
| JP2002501487A (ja) | トリの抗体の使用法 | |
| Casillas et al. | Multicenter evaluation of the efficacy and safety of gatifloxacin in Mexican adult outpatients with respiratory tract infections | |
| JP2025508389A5 (https=) |